United States Patent 8,338,428: Scope, Claims, and US Landscape for Injectable Extended-Release Aripiprazole Without Sustained-Release Matrices

What does US 8,338,428 claim, in plain scope terms?

US 8,338,428 is directed to an injectable, extended-release (ER) aripiprazole suspension that is explicitly free of sustained release matrices, with a defined minimum drug loading and a pharmacokinetic (PK) performance requirement measured as the duration of detectable aripiprazole in plasma after a dose.

Core claim concept (independent claim 1)

Claim 1 requires, in combination:

Dosage form: injectable composition (ER) for injection
No sustained release matrices: “free of sustained release matrices”
Drug component: suspension containing about 50 mg or more aripiprazole
Vehicle: injection vehicle optionally including a viscosity enhancing agent
Drug concentration floor: aripiprazole concentration about 30 mg/mL or more in the injectable composition
PK performance: after injection, aripiprazole is present in plasma for about 7 days or more

That set of requirements is unusually tight because it combines: 1) a formulation limitation (suspension; absence of sustained-release matrices; specific concentration banding via “about 30 mg/mL or more”), and
2) a functional PK endpoint (plasma presence duration thresholds at 7 days and 21 days in dependent claims).

Independent claim 15 (composition with defined vehicle set)

Claim 15 also recites:

Suspension with about 50 mg or more aripiprazole
A vehicle that includes water + viscosity enhancing agent + wetting agent + tonicity agent
Free of sustained release materials
Drug concentration about 30 mg/mL or more
PK presence in plasma 7 days or more

Claim 15 is broader than claim 1 in that it makes the vehicle components part of the required composition (water, viscosity agent, wetting agent, tonicity agent), while claim 1 makes viscosity agent optional.

Dependent claim build-outs that define the vehicle and dosing pattern

The claims specify particular excipients and quantitative thresholds:

Viscosity enhancing agent: carboxymethyl cellulose (CMC) (claim 3)
Vehicle CMC level:
- ≥ 1% v/v sodium carboxymethyl cellulose (claim 4)
- ≥ 3% v/v carboxymethyl cellulose (claim 5)
Wetting agent: polysorbates (claim 7), specifically:
- selected from polysorbate 20/40/80; dependent narrows to polysorbate 20 (claim 8)
- polysorbate 20 at ≥ 0.1% by weight (claim 9)
Density enhancing agent: sorbitol (claim 10-11)
Tonicity adjusting agent: sodium chloride (claim 12-14)
- sodium chloride at ≥ 1% by weight (claim 14)
Defined “example-like” combination (claim 16):
- ~3% v/v CMC
- ~0.1% polysorbate 20
- ~1% by weight NaCl
Method claims (claim 17 onwards):
- administering by injection (claim 17)
- ER performance with plasma presence ≥ 21 days (claim 18)
- administration by intramuscular or subcutaneous injection (claim 19)
- dosing interval:
- every 7 days (claim 20)
- every 14 days (claim 21)
Particle size limitation (claim 22):
- suspension drug particles with mass mean diameter ≤ 100 microns

How do the claims separate formulation vs pharmacokinetic performance?

US 8,338,428 uses two layers of limitation.

1) Formulation boundaries (hard carve-ins)

The composition must be:

Suspension (not a dissolved ER system)
ER in plasma duration sense
Free of sustained release matrices (and claim 15 uses “free of sustained release materials”)
Drug loading:
- mass: ≥ 50 mg aripiprazole
- concentration: ≥ 30 mg/mL
Optional or required vehicle ingredients depending on claim:
- viscosity agent: optional in claim 1; required in claim 15
- CMC as viscosity agent in dependent claims
- polysorbate as wetting agent in dependent claims
- sorbitol as density agent in dependent claims
- NaCl as tonicity agent in dependent claims
Particle size:
- ≤100 microns mass mean diameter in claim 22

2) Functional PK performance (hard endpoints)

Claim 1/15: plasma presence ≥ 7 days
Claim 2/18: plasma presence ≥ 21 days These endpoints are not merely “targets”; they operate as claimed performance requirements.

What is the likely claim construction direction for “free of sustained release matrices”?

The claims distinguish the invention from ER platforms that rely on:

polymeric depots,
micro/nano encapsulation with release control,
implants or in-situ forming sustained-release matrices.

By stating “free of sustained release matrices” (claim 1) and “free of sustained release materials” (claim 15), the claim language pushes coverage toward:

a suspension approach that achieves ER exposure without embedding the drug in a sustained-release matrix.

From an enforcement standpoint, this language is a central vulnerability and a central strength:

Vulnerable to indirect evidence that a candidate formulation uses matrix-like release control.
Strengthened by the absence of “sustained release matrices/materials” as a categorical exclusion, which can be tested against formulation design.

What is the concrete numerical scope (mg/mL, viscosifier, wetting agent, ions, particle size, duration)?

Claim-required thresholds (selected)

Claim	Requirement	Numerical / categorical scope
1	aripiprazole mass	about 50 mg or more
1	aripiprazole concentration	about 30 mg/mL or more
1	PK duration	plasma presence about 7 days or more
2	PK duration	plasma presence about 21 days or more
3	viscosity agent identity	carboxymethyl cellulose
4	sodium CMC level	≥ 1% v/v
5	CMC level	≥ 3% v/v
7	wetting agent options	polysorbate 20/40/80
8	wetting agent identity	polysorbate 20
9	polysorbate 20 level	≥ 0.1% by weight
10-11	density agent	sorbitol
12-14	tonicity agent	sodium chloride, ≥ 1% by weight
16	defined vehicle combination	~3% v/v CMC, ~0.1% polysorbate 20, ~1% by weight NaCl
17	method	inject claim 1 composition
19	route	IM or SC
20-21	dosing interval	every 7 days and every 14 days
22	particle size	mass mean diameter ≤ 100 microns

How do claim 17-22 expand enforcement from composition to method?

The method claims are tied to injecting “the composition of claim 1,” so infringement flows from formulation coverage into administration activities.

Method claim anchor points

Claim 17: administering ER aripiprazole via injection of claim 1 composition
Claim 18: plasma presence ≥ 21 days
Claim 19: route IM or SC
Claim 20: dosing interval every 7 days
Claim 21: dosing interval every 14 days
Claim 22 is still a composition claim (particle size), but it can become relevant to method infringement if the administered product must satisfy the particle-size feature.

What is the competitive patent landscape relevance (where this fits among aripiprazole ER products)?

This patent’s phrasing is aimed at a suspension-based ER approach without sustained-release matrices, with explicit excipient package constraints (CMC, polysorbate, NaCl, sorbitol) and PK duration endpoints.

In practical landscape terms, US 8,338,428 becomes relevant when assessing:

next-generation aripiprazole ER injectables,
suspension formulations that attempt to match long-acting PK without depot polymers,
generic or authorized follow-on products seeking to replicate:
- dosing mass and concentration,
- vehicle excipient package,
- particle size,
- and plasma duration targets.

Freedom-to-operate sensitivity map (what typically drives design-around)

Because the claims are both composition- and PK-endpoint-limited, common design-around levers include:

using a matrix-based ER architecture (which may remove “free of sustained release matrices/materials” compliance but can still be patent-avoiding or patent-infringing depending on other patents),
changing drug concentration below 30 mg/mL,
altering drug mass per dose below 50 mg,
altering particle size above 100 microns,
replacing CMC with another viscosity system, or changing CMC level below thresholds,
replacing polysorbate 20 with another wetting agent (or polysorbate concentration below threshold),
using tonicity control not based on NaCl at the required level,
shifting PK duration performance so that plasma presence does not meet 7 days or 21 days claimed thresholds.

What does the claim set imply about prosecution strategy and enforceability?

Several features suggest an attempt to create enforceable coverage across both “close variations” and “vehicle formulation variants”:

Claim 1 provides a broad formulation-and-PK anchor.
Claim 3-5 and 7-9 and 10-14 define excipient identity and threshold levels.
Claim 16 is a compact quantitative combination that can cover a specific commercial formulation profile.
Claim 22 adds a particle-size limitation that can distinguish among competing suspensions.

The reliance on PK endpoints (7 days and 21 days) provides functional boundaries but can also raise evidentiary needs for infringement proof in litigation, because PK depends on administration conditions and analytical method.

What is the enforcement scope by product timing: 7-day vs 14-day vs 21-day plasma presence?

The claims set two distinct time axes:

Administration interval (method claims):
- every 7 days (claim 20)
- every 14 days (claim 21)
Plasma presence (composition and method endpoints):
- ≥ 7 days (claim 1 and 15)
- ≥ 21 days (claim 2 and 18)

This combination suggests coverage for long persistence after at least one dose and supports a dosing paradigm that can be weekly or biweekly while still meeting a 21-day plasma presence threshold for the formulation.

Where does this patent sit in the broader US aripiprazole ER portfolio from a business lens?

From an investment and R&D standpoint, the key point is not the number of claims, but the type of constraints:

a categorical exclusion (no sustained-release matrices/materials),
fixed quantitative floors (≥50 mg; ≥30 mg/mL),
functional PK duration thresholds (≥7 days; ≥21 days),
and a specific excipient architecture (CMC + polysorbate + NaCl, with sorbitol).

This combination makes the patent a useful defensive boundary in:

line extensions for depot-like suspensions,
platform shifts away from matrix-based depots,
and generic development where formulation and PK must match.

What are the most relevant claim subsets for infringement targeting?

For a candidate product to land inside the strongest part of the claim set, it would typically have to satisfy:

claim 1: no sustained-release matrices + suspension + ≥50 mg + ≥30 mg/mL + plasma presence ≥7 days
and likely one or more excipient and particle-size dependent constraints (CMC, polysorbate 20, NaCl, and ≤100 microns)

The “vehicle package” claims (3-5, 7-9, 12-14, 16) are the most actionable for formulation engineers because they translate to measurable composition specs.

Key Takeaways

US 8,338,428 claims an injectable aripiprazole suspension with no sustained-release matrices/materials that achieves plasma presence ≥7 days after injection, with additional coverage for plasma presence ≥21 days.
The composition scope includes specific quantitative floors: ≥50 mg aripiprazole per dose and ≥30 mg/mL concentration.
Dependent claims narrow the excipient stack to CMC (with ≥1% v/v sodium CMC and ≥3% v/v CMC), polysorbate (notably polysorbate 20 at ≥0.1% by weight), NaCl at ≥1% by weight, and sorbitol as a density enhancer.
Particle size can be limiting at ≤100 microns mass mean diameter.
Method claims extend protection to IM or SC administration and dosing schedules every 7 days or every 14 days, so formulation infringement can convert into activity infringement.

FAQs

1) What is the single most important independent-claim requirement besides “extended release”?
The composition must be free of sustained release matrices/materials while still achieving plasma presence ≥7 days.

2) What numerical drug-loading thresholds drive coverage in claim 1?
About ≥50 mg aripiprazole per injection and about ≥30 mg/mL concentration.

3) How does the patent treat vehicle composition?
Claim 1 makes viscosity agent optional; claim 15 requires a vehicle including viscosity enhancing agent, wetting agent, and tonicity agent with ER performance and no sustained-release materials.

4) Which excipients are explicitly named in dependent claims?
CMC (viscosity), polysorbates (wetting; especially polysorbate 20), sorbitol (density), and sodium chloride (tonicity).

5) Does the patent include a particle-size limitation?
Yes. Claim 22 requires suspension drug particles with mass mean diameter ≤100 microns.

References

[1] United States Patent No. 8,338,428.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	522200	⤷ Start Trial
Australia	2004264886	⤷ Start Trial
Canada	2534997	⤷ Start Trial
China	102133171	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,338,428

Summary for Patent: 8,338,428